<DOC>
	<DOCNO>NCT01465412</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics ( PK ) preladenant administration single 5 mg oral dose preladenant participant hepatic impairment healthy volunteer . Part 1 study compare healthy volunteer participant mild hepatic impairment . Part 2 compare healthy volunteer participant moderate hepatic impairment . Healthy volunteer part study match participant hepatic impairment race , age , gender , body mass index ( BMI ) . The primary hypothesis participant mild moderate HI , area concentration-time curve time 0 extrapolate time last quantifiable concentration ( AUC0-t ) preladenant similar observe matched healthy volunteer , mean ratio hepatic impaired/healthy contain within interval [ 0.50 , 2.00 ] .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Preladenant Participants With Chronic Hepatic Impairment ( P06513 )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Key Inclusion Criteria Healthy Participants Groups : Must healthy normal hepatic function free clinically significant disease condition require physician 's care and/or would interfere study evaluation procedure . Key Inclusion Criteria Hepatic Impaired Groups : Must mild moderate hepatic impairment . Must diagnosis chronic liver disease &gt; 6 month . Clinical laboratory test , physical examination , electrocardiograph must clinically acceptable investigator sponsor . Must free , chronic liver disease , significant medical condition unrelated hepatic disorder except condition opinion investigator may interfere study evaluation , procedure participation . Key Exclusion Criteria Must prohibit medication entry trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Parkinson disease</keyword>
</DOC>